Privia Health Q3 revenue beats estimates

By Reuters News


Overview

  • U.S. physician enablement firm's Q3 revenue rose 13% and beat analyst expectations

  • Q3 adjusted EBITDA beat analyst estimates

  • Company raised full-year 2026 guidance above high end for all key metrics


Outlook

  • Company raises FY 2026 revenue guidance to $2.5 bln-$2.55 bln

  • Company now expects FY 2026 adjusted EBITDA of $154 mln-$157 mln

  • Company sees FY 2026 practice collections of $3.9 bln-$3.95 bln


Result Drivers

  • PROVIDER AND PATIENT GROWTH - Co said increases in implemented providers and value-based care attributed lives contributed to higher revenue and collections

  • REVENUE MIX - Growth in fee-for-service patient care and capitated revenue offset a decline in shared savings and care management fees


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$657 mln

$610.77 mln (16 Analysts)

Q3 EPS

$0.10

Q3 Net Income

$13.50 mln

Q3 Adjusted EBITDA

Beat

$40.60 mln

$39.39 mln (17 Analysts)

Q3 Operating Income

$20.50 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the healthcare facilities & services peer group is "buy"

  • Wall Street's median 12-month price target for Privia Health Group Inc is $31.00, about 38.4% above its November 4 closing price of $22.40

  • The stock recently traded at 55 times the next 12-month earnings vs. a P/E of 70 three months ago


Reuters Recommended Reads

  • Nov 4 - Acadia Healthcare Q3 revenue beats estimates; 2026 outlook raised

  • Nov 4 - Ardent Health Q3 revenue beats analyst estimates

  • Nov 4 - Health insurers, hospitals rally after sweeping midterm win for Democrats


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.